Navigation Links
Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain

s is a clinical stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. In addition to AEG33773, Aegera has three programs in clinical development for oncology indications:

- AEG35156 targets the key anti-apoptotic protein XIAP, and is currently

in multiple Phase II human clinical trials for the treatment of solid

tumors and leukemia;

- AEG41174 is a novel, non-ATP competitive, small molecule tyrosine

kinase inhibitor targeting therapeutically significant kinases

including JAK2 and Bcr-Abl, and is currently in Phase 1 clinical


- AEG40826 (HGS1029) is a small molecule IAP inhibitor that has shown

promising preclinical activity alone and in combination with other

anti-neoplastic agents across a broad range of cancers. A license and

collaboration agreement was executed in December 2007 whereby Human

Genome Sciences, Inc. (Nasdaq: HGSI) acquired exclusive rights to

develop and commercialize small-molecule IAP inhibitors in oncology.


Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Post Your Comments:
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... Talon Innovations, a provider of ... other technology-driven industries, announces that it is one of three finalists for the Minnesota ... On Thursday, September 25 Talon Innovations was recognized as a nominee for this ...
(Date:10/7/2015)... PUNE, India , October 8, 2015 ... --> Medical biotechnology accounts for ... use of bioinformatics in drug discovery and ... with . ... --> On the basis of applications, ...
(Date:10/7/2015)... , ... October 07, 2015 , ... ... ) will present a public educational seminar on the latest advances in ... 10th from 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake Town Square ...
Breaking Biology Technology:
... announces the following Webcast:, What: Transgenomic Inc. ... Conference Call, When: Thursday, February ... , How: Live over the Internet -- ... address above., To access the call via ...
... Pharsight,s Regulatory-Oriented Consulting Unit to Use Pharsight, ... Pre-Clinical and Clinical Data, MOUNTAIN VIEW, ... PHST ), a leading provider of software, ... drug,development, today announced that its Reporting and ...
... (Nasdaq: MEMY ) announced today that it will report,its fourth quarter ... U.S. financial markets open. Management will provide a,Company update and discuss the ... a.m. EST., Investors and other interested parties may ... ...
Cached Biology Technology:
(Date:9/28/2015)... -- According to a new market research ... & Others), Application (Access Control & Others), Industry (Travel ... Global - Forecast to 2020", published by MarketsandMarkets, the Iris ... by 2020, at a CAGR of 23.40% between 2015 ... T ables and 66 Figures spread ...
(Date:9/24/2015)...  EyeLock LLC, a market leader of iris-based identity ... latest technology in Booth #602 at next week,s ASIS ... EyeLock,s iris authentication technology provides an unprecedented level ... it the most proven way to authenticate one,s identity ... deliver a fast and friendly user experience to identify ...
(Date:9/10/2015)... Report Details Emerging Biological ... and Revenue Prospects to Help You Stay Ahead ... new drug classes? Get the latest technological and ... market data and industry knowledge, benefitting your influence. ... and sales predictions. Visiongain,s new study reveals ...
Breaking Biology News(10 mins):
... discovered a new corticosteroid hormone in the sea lamprey, ... dating back 500 million years. These findings have shed ... help conservation and management efforts for lampreys. "This ... lamprey conservation," says principal investigator and lead author David ...
... graham crackers might be one way to get children to ... of Minnesota shows. Federal nutrition guidelines recommend at least ... have found that children typically only eat about one serving ... texture of whole-grain foods. In this study, researchers served ...
... Allergy and Infections Disease has awarded a five-year ... is leading a consortium of academic medical centers ... atopic dermatitis. The researchers will focus on antibiotic-resistant ... of the skin, both of which are more ...
Cached Biology News:
Request Info...
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: